Cargando…
Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
In this prospective observational study, data were collected from 34 rheumatology clinics in Italy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who started golimumab (GLM) as a second anti-TNFα drug. The primary objective was to evaluate t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322086/ https://www.ncbi.nlm.nih.gov/pubmed/35887946 http://dx.doi.org/10.3390/jcm11144178 |
_version_ | 1784756210651627520 |
---|---|
author | D’Angelo, Salvatore Tirri, Enrico Giardino, Angela Maria Mattucci-Cerinic, Marco Dagna, Lorenzo Santo, Leonardo Ciccia, Francesco Frediani, Bruno Govoni, Marcello Bobbio Pallavicini, Francesca Grembiale, Rosa Daniela Delle Sedie, Andrea Mulè, Rita Cantatore, Francesco Paolo Foti, Rosario Gremese, Elisa Conigliaro, Paola Salaffi, Fausto Viapiana, Ombretta Cauli, Alberto Giacomelli, Roberto Arcarese, Luisa Guggino, Giuliana Russo, Romualdo Puenpatom, Amy Capocotta, Domenico Nacci, Francesca Anelli, Maria Grazia Picerno, Valentina Binetti, Corrado Iannone, Florenzo |
author_facet | D’Angelo, Salvatore Tirri, Enrico Giardino, Angela Maria Mattucci-Cerinic, Marco Dagna, Lorenzo Santo, Leonardo Ciccia, Francesco Frediani, Bruno Govoni, Marcello Bobbio Pallavicini, Francesca Grembiale, Rosa Daniela Delle Sedie, Andrea Mulè, Rita Cantatore, Francesco Paolo Foti, Rosario Gremese, Elisa Conigliaro, Paola Salaffi, Fausto Viapiana, Ombretta Cauli, Alberto Giacomelli, Roberto Arcarese, Luisa Guggino, Giuliana Russo, Romualdo Puenpatom, Amy Capocotta, Domenico Nacci, Francesca Anelli, Maria Grazia Picerno, Valentina Binetti, Corrado Iannone, Florenzo |
author_sort | D’Angelo, Salvatore |
collection | PubMed |
description | In this prospective observational study, data were collected from 34 rheumatology clinics in Italy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who started golimumab (GLM) as a second anti-TNFα drug. The primary objective was to evaluate the effectiveness of GLM after 6 months. Changes in quality of life using the EQ-5D-5L were also assessed. A total of 194 patients aged 53.2 ± 12 years started GLM as a second anti-TNF drug: 39 (20.1%) with RA, 91 (46.9%) with PsA and 64 (32.9%) with axSpA. After 6 months of GLM treatment, 68% of RA patients achieved low disease activity (LDA; DAS28-CRP ≤ 3.2), 31.9% of PsA patients achieved minimal disease activity and 32.5% of axSpA patients achieved LDA (ASDAS-CRP < 2.1). Good/moderate EULAR response was achieved in 61.9% and 73.8% of patients with RA and PsA, respectively, and 16% of axSpA patients achieved a 50% improvement in BASDAI. Across all indications, improvements in disease activity measures and EQ-5D-5L domains were observed over 6 months. The main reasons for GLM interruption were lack/loss of efficacy (7.2%) or adverse events (2%). This study confirms the effectiveness of GLM as a second-line anti-TNF for the treatment of RA, PsA and axSpA in a real-world setting in Italy. |
format | Online Article Text |
id | pubmed-9322086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93220862022-07-27 Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study D’Angelo, Salvatore Tirri, Enrico Giardino, Angela Maria Mattucci-Cerinic, Marco Dagna, Lorenzo Santo, Leonardo Ciccia, Francesco Frediani, Bruno Govoni, Marcello Bobbio Pallavicini, Francesca Grembiale, Rosa Daniela Delle Sedie, Andrea Mulè, Rita Cantatore, Francesco Paolo Foti, Rosario Gremese, Elisa Conigliaro, Paola Salaffi, Fausto Viapiana, Ombretta Cauli, Alberto Giacomelli, Roberto Arcarese, Luisa Guggino, Giuliana Russo, Romualdo Puenpatom, Amy Capocotta, Domenico Nacci, Francesca Anelli, Maria Grazia Picerno, Valentina Binetti, Corrado Iannone, Florenzo J Clin Med Article In this prospective observational study, data were collected from 34 rheumatology clinics in Italy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who started golimumab (GLM) as a second anti-TNFα drug. The primary objective was to evaluate the effectiveness of GLM after 6 months. Changes in quality of life using the EQ-5D-5L were also assessed. A total of 194 patients aged 53.2 ± 12 years started GLM as a second anti-TNF drug: 39 (20.1%) with RA, 91 (46.9%) with PsA and 64 (32.9%) with axSpA. After 6 months of GLM treatment, 68% of RA patients achieved low disease activity (LDA; DAS28-CRP ≤ 3.2), 31.9% of PsA patients achieved minimal disease activity and 32.5% of axSpA patients achieved LDA (ASDAS-CRP < 2.1). Good/moderate EULAR response was achieved in 61.9% and 73.8% of patients with RA and PsA, respectively, and 16% of axSpA patients achieved a 50% improvement in BASDAI. Across all indications, improvements in disease activity measures and EQ-5D-5L domains were observed over 6 months. The main reasons for GLM interruption were lack/loss of efficacy (7.2%) or adverse events (2%). This study confirms the effectiveness of GLM as a second-line anti-TNF for the treatment of RA, PsA and axSpA in a real-world setting in Italy. MDPI 2022-07-19 /pmc/articles/PMC9322086/ /pubmed/35887946 http://dx.doi.org/10.3390/jcm11144178 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article D’Angelo, Salvatore Tirri, Enrico Giardino, Angela Maria Mattucci-Cerinic, Marco Dagna, Lorenzo Santo, Leonardo Ciccia, Francesco Frediani, Bruno Govoni, Marcello Bobbio Pallavicini, Francesca Grembiale, Rosa Daniela Delle Sedie, Andrea Mulè, Rita Cantatore, Francesco Paolo Foti, Rosario Gremese, Elisa Conigliaro, Paola Salaffi, Fausto Viapiana, Ombretta Cauli, Alberto Giacomelli, Roberto Arcarese, Luisa Guggino, Giuliana Russo, Romualdo Puenpatom, Amy Capocotta, Domenico Nacci, Francesca Anelli, Maria Grazia Picerno, Valentina Binetti, Corrado Iannone, Florenzo Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study |
title | Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study |
title_full | Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study |
title_fullStr | Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study |
title_full_unstemmed | Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study |
title_short | Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study |
title_sort | effectiveness of golimumab as second anti-tnfα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in italy: go-beyond, a prospective real-world observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322086/ https://www.ncbi.nlm.nih.gov/pubmed/35887946 http://dx.doi.org/10.3390/jcm11144178 |
work_keys_str_mv | AT dangelosalvatore effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT tirrienrico effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT giardinoangelamaria effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT mattuccicerinicmarco effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT dagnalorenzo effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT santoleonardo effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT cicciafrancesco effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT fredianibruno effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT govonimarcello effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT bobbiopallavicinifrancesca effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT grembialerosadaniela effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT dellesedieandrea effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT mulerita effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT cantatorefrancescopaolo effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT fotirosario effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT gremeseelisa effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT conigliaropaola effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT salaffifausto effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT viapianaombretta effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT caulialberto effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT giacomelliroberto effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT arcareseluisa effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT gugginogiuliana effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT russoromualdo effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT puenpatomamy effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT capocottadomenico effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT naccifrancesca effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT anellimariagrazia effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT picernovalentina effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT binetticorrado effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy AT iannoneflorenzo effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy |